XML 48 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Segments of Business and Geographic Areas (Tables)
 3 Months Ended
Apr. 04, 2021
Mar. 29, 2020
Segment Reporting [Abstract]    
Sales By Segment Of Business
SALES BY SEGMENT OF BUSINESS
 Fiscal First Quarter Ended
(Dollars in Millions)April 4,
2021		March 29,
2020		Percent
Change
Consumer Health   
OTC
     U.S.$599 689 (13.0)%
     International575 659 (12.8)
     Worldwide 1,175 1,348 (12.9)
Skin Health/Beauty
     U.S.634 659 (3.9)
     International529 458 15.7 
     Worldwide 1,163 1,117 4.1 
Oral Care
     U.S.163 176 (7.2)
     International254 219 16.0 
     Worldwide 417 395 5.7 
Baby Care
     U.S.96 92 4.2 
     International293 269 8.9 
     Worldwide 389 361 7.7 
Women's Health
     U.S.3 4 (25.8)
     International219 228 (3.9)
     Worldwide 222 232 (4.3)
Wound Care/Other
     U.S.115 119 (3.0)
     International61 52 17.6 
     Worldwide 177 171 3.3 
TOTAL Consumer Health
     U.S.1,611 1,740 (7.4)
     International1,932 1,885 2.5 
     Worldwide 3,543 3,625 (2.3)
PHARMACEUTICAL
Immunology
     U.S.2,413 2,410 0.1 
     International1,501 1,228 22.3 
     Worldwide 3,914 3,638 7.6 
     REMICADE®
     U.S.489 625 (21.7)
     U.S. Exports57 110 (48.4)
     International232 256 (9.4)
     Worldwide 777 990 (21.5)
     SIMPONI / SIMPONI ARIA®
     U.S.255 272 (5.9)
     International307 258 18.9 
     Worldwide 562 529 6.2 
     STELARA®
     U.S.1,331 1,217 9.4 
     International817 603 35.6 
     Worldwide 2,148 1,819 18.1 
     TREMFYA®
     U.S.274 187 46.3 
     International143 109 32.0 
     Worldwide 418 296 41.0 
     OTHER IMMUNOLOGY
     U.S.7 — *
     International2 3 (38.4)
     Worldwide 8 3 *
Infectious Diseases
     U.S.512 436 17.4 
     International494 483 2.3 
     Worldwide 1,007 920 9.5 
     COVID-19 vaccine
     U.S.100 — *
     International— — —
     Worldwide100 — *
     EDURANT® / rilpivirine
     U.S.10 12 (12.3)
     International233 212 9.8 
     Worldwide 243 224 8.6 
     PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
     U.S.380 396 (3.8)
     International166 184 (9.9)
     Worldwide 546 579 (5.8)
     OTHER INFECTIOUS DISEASES
     U.S.21 29 (27.0)
     International96 87 9.7 
     Worldwide 117 116 0.6 
Neuroscience
     U.S.771 748 3.2 
     International949 910 4.3 
     Worldwide 1,721 1,658 3.8 
     CONCERTA® / methylphenidate
     U.S.47 52 (9.6)
     International123 118 4.5 
     Worldwide 171 171 0.2 
     INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
     U.S.589 544 8.3 
     International376 339 11.0 
     Worldwide 965 883 9.4 
     RISPERDAL CONSTA®
     U.S.67 76 (11.8)
     International89 94 (4.8)
     Worldwide 157 170 (7.9)
     OTHER NEUROSCIENCE
     U.S.67 75 (9.8)
     International361 360 0.2 
     Worldwide 428 435 (1.5)
Oncology
     U.S.1,377 1,175 17.2 
     International2,193 1,839 19.3 
     Worldwide 3,570 3,013 18.5 
     DARZALEX®
     U.S.691 463 49.2 
     International674 474 42.2 
     Worldwide 1,365 937 45.6 
     ERLEADA®
     U.S.171 119 44.0 
     International90 24  *
     Worldwide 261 143 82.8 
     IMBRUVICA®
     U.S.444 432 2.8 
     International680 599 13.5 
     Worldwide 1,125 1,031 9.0 
     ZYTIGA® / abiraterone acetate
     U.S.50 139 (64.2)
     International588 552 6.6 
     Worldwide 638 690 (7.6)
     OTHER ONCOLOGY(1)
     U.S.21 22 (5.1)
     International161 190 (15.3)
     Worldwide 182 212 (14.2)
Pulmonary Hypertension
     U.S.573 486 18.0 
     International288 260 10.8 
     Worldwide 861 745 15.5 
     OPSUMIT®
     U.S.272 229 18.5 
     International179 160 11.5 
     Worldwide 450 389 15.6 
     UPTRAVI®
     U.S.259 212 21.9 
     International46 38 23.0 
     Worldwide 305 250 22.0 
     OTHER PULMONARY HYPERTENSION
     U.S.42 44 (3.5)
     International63 62 1.4 
     Worldwide 105 106 (0.6)
Cardiovascular / Metabolism / Other
     U.S.799 806 (0.9)
     International328 354 (7.2)
     Worldwide 1,127 1,160 (2.8)
     XARELTO®
     U.S.589 527 11.7 
     International— — — 
     Worldwide 589 527 11.7 
     INVOKANA® / INVOKAMET®
     U.S.87 117 (26.1)
     International63 58 9.2 
     Worldwide 150 175 (14.4)
     PROCRIT® / EPREX®
     U.S.62 76 (18.3)
     International64 79 (18.1)
     Worldwide 127 155 (18.2)
     OTHER
     U.S.60 85 (28.8)
     International201 217 (7.7)
     Worldwide 261 302 (13.6)
TOTAL PHARMACEUTICAL  
     U.S.6,446 6,061 6.4 
     International5,753 5,073 13.4 
     Worldwide 12,199 11,134 9.6 
MEDICAL DEVICES
Interventional Solutions
     U.S.434 365 19.0 
     International514 362 42.0 
     Worldwide 949 727 30.4 
Orthopaedics
     U.S.1,249 1,250 (0.1)
     International864 788 9.7 
     Worldwide 2,113 2,038 3.7 
     HIPS
     U.S.210 206 2.4 
     International146 132 11.2 
     Worldwide 357 337 5.8 
     KNEES
     U.S.185 214 (13.5)
     International132 130 2.0 
     Worldwide 317 343 (7.6)
     TRAUMA
     U.S.450 407 10.7 
     International282 247 14.4 
     Worldwide 733 654 12.1 
     SPINE, SPORTS & OTHER
     U.S.403 423 (4.8)
     International303 280 8.4 
     Worldwide 706 703 0.4 
Surgery
     U.S.898 844 6.5 
     International1,474 1,257 17.3 
     Worldwide 2,372 2,100 12.9 
     ADVANCED
     U.S.405 381 6.5 
     International713 567 25.7 
     Worldwide 1,118 948 18.0 
     GENERAL
     U.S.493 463 6.5 
     International761 690 10.3 
     Worldwide 1,254 1,153 8.8 
Vision
     U.S.472 439 7.4 
     International673 628 7.3 
     Worldwide 1,145 1,067 7.3 
     CONTACT LENSES / OTHER
     U.S.371 346 7.2 
     International486 467 4.0 
     Worldwide 857 814 5.3 
     SURGICAL
     U.S.101 93 8.2 
     International187 160 17.0 
     Worldwide 288 253 13.7 
TOTAL MEDICAL DEVICES  
     U.S.3,054 2,898 5.4 
     International3,525 3,034 16.2 
     Worldwide 6,579 5,932 10.9 
WORLDWIDE   
     U.S.11,111 10,699 3.9 
     International11,210 9,992 12.2 
     Worldwide $22,321 20,691 7.9 %
*Percentage greater than 100% or not meaningful
(1) Inclusive of VELCADE® which was previously disclosed separately
  
Operating Profit by Segment of Business  
EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
 Fiscal First Quarter Ended
(Dollars in Millions)April 4,
2021		March 29,
2020		Percent
Change
Consumer Health (1)
$788 770 2.3%
Pharmaceutical(2)
5,223 3,834 36.2
Medical Devices(3)
1,629 2,025 (19.6)
Segment earnings before provision for taxes7,640 6,629 15.3
Less: Expense not allocated to segments (4)
211 120  
Worldwide income before tax$7,429 6,509 14.1%

(1) Consumer Health
•Includes amortization expense of $0.1 billion in both the fiscal first quarter of 2021 and 2020.
(2) Pharmaceutical
•Includes divestiture gains of $0.6 billion in the fiscal first quarter of 2021 related to two brands outside the U.S.
•Includes an unrealized loss on securities of $0.3 billion in the fiscal first quarter of 2020.
•Includes litigation expense of $0.1 billion in the fiscal first quarter of 2020.
•Includes amortization expense of $0.9 billion and $0.8 billion in the fiscal first quarter of 2021 and 2020, respectively.

In fiscal 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.0 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.
(3) Medical Devices
•Includes a contingent consideration reversal of $1.0 billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition.
•Includes a restructuring related charge of $0.1 billion in both the fiscal first quarter of 2021 and 2020, respectively.
•Includes amortization expense of $0.3 billion and $0.2 billion in the fiscal first quarter of 2021 and 2020, respectively.
(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
SALES BY GEOGRAPHIC AREA
 Fiscal First Quarter Ended
(Dollars in Millions)April 4, 2021March 29, 2020Percent
Change
United States$11,111 10,699 3.9 %
Europe5,414 4,827 12.1 
Western Hemisphere, excluding U.S.1,424 1,502 (5.1)
Asia-Pacific, Africa4,372 3,663 19.4 
Total$22,321 20,691 7.9 %